MX9602495A - Peptidos novedosos derivados de autoantigeno para usarse en inmunoterapia de enfermedades autoinmunes. - Google Patents

Peptidos novedosos derivados de autoantigeno para usarse en inmunoterapia de enfermedades autoinmunes.

Info

Publication number
MX9602495A
MX9602495A MX9602495A MX9602495A MX9602495A MX 9602495 A MX9602495 A MX 9602495A MX 9602495 A MX9602495 A MX 9602495A MX 9602495 A MX9602495 A MX 9602495A MX 9602495 A MX9602495 A MX 9602495A
Authority
MX
Mexico
Prior art keywords
autoantigen
peptides
seq
autoimmune diseases
peptides derived
Prior art date
Application number
MX9602495A
Other languages
English (en)
Inventor
Anna Maria Helena Boots
Gijsbertus Franciscus Verheij
Den
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of MX9602495A publication Critical patent/MX9602495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a péptidos novedosos derivados del autoantígeno gp-39 CH, dichos péptidos comprendiendo, por lo menos, una de las secuencias de aminoácidos FGRSFTLAS (SEX ID No. 1), FTLASSETG (SEX ID No. 2), YDDQESVKS (SEC ID No. 3) Y FSKIASNTQ (SEC ID No. 4). Los péptidos se asemejan a epítopes de células T restringidas de CHM Clase II presentes en el autoantígeno gp-39 CH en cartílago articular. El gp-39 CH y dichos péptidos, se pueden usar en tratamiento específico de antígeno de destruccion de cartílago articular en enfermedades autoinmunes para inducir tolerancia del sistema inmune. El autoantígeno gp-39 CH y dichos péptidos, también son adecuados para inducir artritis en animales no humanos, preferiblemente ratones. La invencion se refiere además a composiciones farmacéuticas comprendiendo dicho autoantígeno y/o dichos péptidos, un método de diagnostico para la deteccion de células T autorreactivas en una muestra de prueba y equipos de prueba para usarse en dicho método.
MX9602495A 1994-10-27 1995-10-25 Peptidos novedosos derivados de autoantigeno para usarse en inmunoterapia de enfermedades autoinmunes. MX9602495A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203128 1994-10-27
EP95200886 1995-04-07
PCT/EP1995/004201 WO1996013517A1 (en) 1994-10-27 1995-10-25 Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases

Publications (1)

Publication Number Publication Date
MX9602495A true MX9602495A (es) 1997-05-31

Family

ID=26136688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9602495A MX9602495A (es) 1994-10-27 1995-10-25 Peptidos novedosos derivados de autoantigeno para usarse en inmunoterapia de enfermedades autoinmunes.

Country Status (24)

Country Link
US (1) US5736507A (es)
EP (1) EP0733065B1 (es)
JP (1) JP3755894B2 (es)
KR (1) KR100485979B1 (es)
CN (1) CN1161379C (es)
AT (1) ATE177756T1 (es)
AU (1) AU696827B2 (es)
BR (1) BR9506377A (es)
CA (1) CA2173874A1 (es)
DE (1) DE69508380T2 (es)
DK (1) DK0733065T3 (es)
ES (1) ES2130672T3 (es)
FI (1) FI118472B (es)
GR (1) GR3030296T3 (es)
HK (1) HK1002012A1 (es)
HU (1) HU218027B (es)
IL (1) IL115744A (es)
MX (1) MX9602495A (es)
NO (1) NO316703B1 (es)
NZ (1) NZ295659A (es)
PL (1) PL183761B1 (es)
RU (1) RU2178797C2 (es)
TR (1) TR199501326A2 (es)
WO (1) WO1996013517A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
IL120561A0 (en) 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
US6881824B1 (en) 1996-04-24 2005-04-19 Akzo Nobel N.V. Peptides suitable for use in antigen specific immunosuppressive therapy
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
KR20010071020A (ko) * 1998-07-23 2001-07-28 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 자가 면역 질환의 면역 요법에서 사용하기 위한 신규한펩티드
JP2002521344A (ja) * 1998-07-23 2002-07-16 アクゾ・ノベル・エヌ・ベー 免疫疾患におけるＨＣｇｐ−３９の使用
IL148778A0 (en) * 1999-10-18 2002-09-12 Akzo Nobel Nv Modified peptides and peptidomimetics for use in immunotherapy
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
EP1418813A4 (en) * 2001-07-24 2009-03-04 Univ Yale METHODS, COMPOSITIONS AND NEEDS RELATING TO CHITINASE AND CHITINASE MOLECULES AND INFLAMMATORY DISEASES
EP1729805A4 (en) * 2004-02-25 2008-11-26 Medimmune Inc METHODS AND COMPOSITIONS RELATED TO CHITINASES AND CHITINASE-MOLECULARS AND MODULATION OF OSTEOCLASTS
US20070071746A1 (en) * 2005-08-31 2007-03-29 Medimmune, Inc. C/CLP antagonists and methods of use thereof
RU2302872C9 (ru) * 2006-06-22 2008-12-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее функции хрящевой ткани, и способ его получения
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US9340580B2 (en) 2007-08-15 2016-05-17 Circassia Limited Peptide with multiple epitopes
EP2331124A1 (en) * 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
EP2153841B2 (en) 2008-08-15 2015-11-11 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
EP2393830B8 (en) 2009-02-05 2015-03-18 Circassia Limited Grass peptides for vaccine
AU2010311515B2 (en) * 2009-10-27 2014-02-20 Erytech Pharma Composition to induce specific immune tolerance
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6323898A (ja) * 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices

Also Published As

Publication number Publication date
JPH09507861A (ja) 1997-08-12
HU9601401D0 (en) 1996-07-29
CN1161379C (zh) 2004-08-11
DK0733065T3 (da) 1999-10-11
FI962619A0 (fi) 1996-06-25
JP3755894B2 (ja) 2006-03-15
DE69508380D1 (de) 1999-04-22
US5736507A (en) 1998-04-07
PL315198A1 (en) 1996-10-14
TR199501326A2 (tr) 1996-06-21
CA2173874A1 (en) 1996-05-09
DE69508380T2 (de) 1999-09-09
HU218027B (hu) 2000-05-28
NO316703B1 (no) 2004-04-13
HK1002012A1 (en) 1998-07-24
AU3925295A (en) 1996-05-23
KR960705848A (ko) 1996-11-08
FI118472B (fi) 2007-11-30
IL115744A (en) 2000-07-16
NO962695L (no) 1996-06-26
HUT74847A (en) 1997-02-28
IL115744A0 (en) 1996-01-19
RU2178797C2 (ru) 2002-01-27
FI962619A (fi) 1996-06-25
PL183761B1 (pl) 2002-07-31
WO1996013517A1 (en) 1996-05-09
NZ295659A (en) 1998-02-26
NO962695D0 (no) 1996-06-26
AU696827B2 (en) 1998-09-17
EP0733065B1 (en) 1999-03-17
GR3030296T3 (en) 1999-09-30
ES2130672T3 (es) 1999-07-01
ATE177756T1 (de) 1999-04-15
EP0733065A1 (en) 1996-09-25
KR100485979B1 (ko) 2006-01-27
BR9506377A (pt) 1997-09-16
CN1168677A (zh) 1997-12-24

Similar Documents

Publication Publication Date Title
MX9602495A (es) Peptidos novedosos derivados de autoantigeno para usarse en inmunoterapia de enfermedades autoinmunes.
Ugrinovic et al. A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis.
NZ332311A (en) Use of autoantigen HC gp-39 and proteins structurally related thereto in immunotherapy of autoimmune diseases particularly rheumatoid arthritis
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
ATE252640T1 (de) Verbindungen zur immunotherapie und diagnose von tuberkulose
NO962426L (no) Spermieantigen som tilsvarer et spermie zonabindende protein autoantigenepitop
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
NZ332427A (en) Peptides suitable for use in antigen specific immunosuppressive therapy
EP0751780A4 (en) METHOD FOR ISOLATING CDA-PRESENTED ANTIGENS, CD1-PRESENTED ANTIGEN-CONTAINING VACCINES, AND CELL LINES USED IN Said PROCEDURE
IL118524A0 (en) Peptides and pharmaceutical compositions containing them
Levy et al. Role of self and foreign antigenic determinants in allogeneic and self-restricted cytotoxic T cell recognition.
Benacerraf Biological function of HLA molecules
EP1986011A3 (en) Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
Buus et al. The Interaction between MHC Class II Molecules and Immunogenic Peptides
Schwarzfischer et al. The HLA system Red cell antigens and their molecular basis Monoclonal antibodies in blood group serology Serum protein systems Biostatistics and computerisation

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: N.V. ORGANON.*

MM Annulment or lapse due to non-payment of fees